Medical Supplies Market worth $248.03 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets projects the global medical supplies market will grow from $194.76 billion in 2026 to $248.03 billion by 2031, a 7.39% CAGR, supported by chronic-disease prevalence, diagnostic testing, infection control and healthcare-infrastructure spending. North America held 40.75% of the market in 2025, while Asia Pacific is expected to grow fastest at a 10.2% CAGR; diagnostic supplies led in 2025 and are projected to be the fastest-growing category. Sector consolidation is focused on recurring-revenue homecare and diabetes-supply businesses, including Cardinal Health's $1.1 billion acquisition of Advanced Diabetes Supply Group.

Analysis

This is not an earnings-revision catalyst: third-party TAM forecasts rarely move large-cap medtech valuations absent corroborating procedure-volume, utilization, or reimbursement data. The more investable read-through is mix: recurring, clinically embedded consumables can sustain pricing and gross-margin resilience, while broad-line distribution remains exposed to contract repricing, labor/logistics costs, and customer concentration. BDX, ABT and TMO are better positioned to monetize a higher-consumables intensity than diversified device peers whose revenue remains more capital-equipment and procedure-cycle dependent.

CAH is the most direct public-market expression of the shift toward direct-to-patient chronic-care fulfillment, but the key debate is not top-line growth; it is whether acquired homecare revenue lifts segment margin and reduces working-capital volatility. A successful integration would support multiple expansion over the next 2-4 quarters, whereas slower payer onboarding, reimbursement pressure, or elevated inventory days would expose the low-margin distribution model. BAX remains a less clean beneficiary: consumables demand helps, but restructuring execution and portfolio complexity can absorb the incremental growth.

Second-order beneficiaries over 6-18 months are focused wound-care and continence franchises, including CTEC and Coloplast (COLO-B.CO), where home-based care raises recurring utilization and lowers hospital dependence. Conversely, hospital purchasing organizations can use scale and fragmented supplier markets to keep commodity-category price increases below cost inflation, limiting upside for undifferentiated suppliers. The source contains clear internal data-quality errors, including an unrelated competitive-share table; treat its projections as directional only and require company-level confirmation before underwriting estimates.

Contrarian view: consensus may over-attribute broad healthcare-supply growth to diagnostics. Routine test volumes are often reimbursement-constrained and can be offset by price declines, making DGX and TMO less pure beneficiaries than the narrative suggests. The higher-conviction signal would be evidence of durable patient enrollment in chronic-care supply channels, not aggregate industry growth estimates.

Key Decisions for Investors

• No immediate market-wide trade: maintain a watchlist rather than adding beta on this release. Require 1-2 quarterly reports showing consumables growth above management plans and stable gross margin before treating the theme as an earnings catalyst.
• Bias long BDX over BAX on a 6-12 month horizon: BDX offers greater recurring-consumables exposure and a cleaner margin-compounding setup, while BAX carries higher restructuring and execution uncertainty. Falsify if BDX organic consumables growth decelerates for two consecutive quarters or gross margin contracts despite stable volumes.
• Monitor CAH for a tactical long after the next at-Home Solutions disclosure; initiate only if patient growth and segment profitability demonstrate accretion without a material increase in receivable or inventory days. Target 10-15% upside versus 7-8% downside, with a stop on integration-related guidance reduction.
• Consider a 6-18 month relative-value pair long CTEC / short BAX, sized modestly: advanced wound care has a more differentiated, recurring homecare demand profile than broad commodity-heavy supplies. Exit if CTEC procedure utilization or reimbursement trends weaken, or if BAX delivers restructuring savings materially ahead of plan.